TABLE 4

Molecular characteristics of 25 observed treatment failures during therapeutic efficacy studies in Zaire and Uíge Provinces, Angola, in 2013

Patient ID no.Treatment armaClassificationbMOIcResistance marker(s) on day 0 and day of failured
pfmdr1eSNPfK13
CNHaplotypeChr 10Chr 13
B313gAL-ZETF21NYDwtwtwt
A111AL-URECR11NFDwtwtwt
A145AL-URECR11NYDwtwtwt
B314AL-ZRECR11NYDwtwtwt
B384AL-ZRECR11NYDwtwtwt
B385AL-ZRECR21NFDwtwtwt
B399AL-ZRECR21NFDwtwtwt
B404AL-ZRECR21NFDwtwtwt
B416AL-ZRECR21NYDwtwtwt
B422AL-ZRECR2/11NYD+NFD/NYDwtwtwt
A114AL-UREIN11NYDwtwtwt
A115AL-UREIN2/11YFD/YYDwtwtwt
A144AL-UREIN4/11NYDwtwtwt
A171AL-UREIN1/21YYD/NFDwtwtwt
B304AL-ZREIN11NFDwtwtwt
B312AL-ZREIN11NYDwtwtwt
B371AL-ZREIN21NFDwtwtwt
B375AL-ZREIN1/21NFD/YYDwtwtwt
B386AL-ZREIN11YYY/NYDwtwtwt
B387AL-ZREIN11NFY/NYDwtwtwt
B398AL-ZREIN11NYDwtwtwt
B402AL-ZREIN2/11YYY/NYDwtwtwt
B421AL-ZREIN1/21NYD/NFDwtwtwt
B423AL-ZREIN1/21NFD/NYDwtwtwt
C560DP-ZREIN11YYDwtwtwt
  • a AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; Z, Zaire; U, Uíge.

  • b ETF, early treatment failure; RECR, recrudescence; REIN, reinfection.

  • c Multiplicities of infection (MOI) either are the same for day 0 and the day of failure or are reported as day 0 MOI/day of failure MOI.

  • d Resistance markers either are the same for day 0 and the day of failure or are reported as day 0/day of failure. wt, wild type.

  • e “CN” represents the P. falciparum multidrug resistance gene 1 copy number, and “haplotype” represents the haplotype constructed from mutations N86Y, Y184F, and D1246Y.

  • f Shown are the chromosome 10 (Chr 10) SNP at position 688956 and Chr 13 SNP at position 1718319 associated with artemisinin resistance.

  • g Molecular data for early treatment failure are available for day 0 only.